Primary hyperparathyroidism and fracture probability.


Journal

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 08 04 2022
accepted: 28 11 2022
pubmed: 17 12 2022
medline: 11 2 2023
entrez: 16 12 2022
Statut: ppublish

Résumé

The incidence of hip and major osteoporotic fracture was increased in patients with primary hyperparathyroidism even in patients not referred for parathyroidectomy. The risk of death was also increased which attenuated an effect on fracture probabilities. The findings argue for widening the indications for parathyroidectomy in mild primary hyperparathyroidism. Primary hyperparathyroidism (PHPT) is associated with an increase in the risk of fracture. In FRAX, the increase in risk is assumed to be mediated by low bone mineral density (BMD). However, the risk of death is also increased and its effect on fracture probability is not known. The aim of this study was to determine whether PHPT affects hip fracture and major osteoporotic fracture risk independently of bone mineral density (BMD) and whether this and any increase in mortality affects the assessment of fracture probability. A register-based survey of patients with PHPT and matched controls in Denmark were identified from hospital registers. The incidence of death, hip fracture, and major osteoporotic fracture were determined for computing fracture probabilities excluding time after parathyroidectomy. The gradient of risk for fracture for differences in BMD was determined in a subset of patients and in BMD controls. The severity of disease was based on serum calcium and parathyroid hormone levels. We identified 6884 patients with biochemically confirmed PHPT and 68,665 matched population controls. On follow-up, excluding time after parathyroidectomy in those undergoing surgery, patients with PHPT had a higher risk of death (+52%), hip fracture (+48%), and major osteoporotic fracture (+36%) than population controls. At any given age, average 10-year probabilities of fracture were higher in patients with PHPT than population controls. The gradient of fracture risk with differences in BMD was similar in cases and controls. Results were similar when confined to patients not undergoing parathyroidectomy. Fracture probability decreased with the severity of disease due to an increase in mortality rather than fracture risk. The risk of hip and other major osteoporotic fracture is increased in PHPT irrespective of the disease severity. Fracture probability was attenuated due to the competing effect of mortality. The increased fracture risk in patients treated conservatively argues for widening the indications for parathyroidectomy in mild PHPT.

Identifiants

pubmed: 36525071
doi: 10.1007/s00198-022-06629-y
pii: 10.1007/s00198-022-06629-y
doi:

Substances chimiques

Parathyroid Hormone 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

489-499

Subventions

Organisme : Medical Research Council
ID : MC_PC_21003
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_21022
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A620_1015
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/2
Pays : United Kingdom

Investigateurs

Tanja Sikjær (T)
Lars Rolighed (L)
Mette Friberg Hitz (MF)
Pia Eiken (P)
Anne Pernille Hermann (AP)
Jens-Erik Beck Jensen (JB)
Lise Sofie Bislev (LS)

Informations de copyright

© 2022. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.

Références

Bilezikian JP (2018) Primary hyperparathyroidism. J Clin Endocrinol Metab 103:3993–4004
doi: 10.1210/jc.2018-01225
Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 99:3561–3569
doi: 10.1210/jc.2014-1413
Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solórzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE (2016) The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151:959–968
doi: 10.1001/jamasurg.2016.2310
Seib CD, Meng T, Suh I, Harris AHS, Covinsky KE, Shoback DM, Trickey AW, Kebebew E, Tamura MK (2022) Risk of fracture among older adults with primary hyperparathyroidism receiving parathyroidectomy vs nonoperative management. JAMA Intern Med 182:10–18. https://doi.org/10.1001/jamainternmed.2021.6437
doi: 10.1001/jamainternmed.2021.6437
Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D’Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28:1–19
doi: 10.1007/s00198-016-3716-2
Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, Ebeling PR, Formenti AM, Frost M, Gosnell J, Lewiecki EM, Singer FR, Gittoes N, Khan AA, Marcocci C, Rejnmark L, Ye Z, Guyatt G, Potts JT (2022) Task Force #8: Management of primary hyperparathyroidism. J Bone Miner Res https://doi.org/10.1002/jbmr.4682
Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Available at https://www.sheffield.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf , accessed 4 April 2022
Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A brief history of FRAX. Arch Osteoporos 13:118. https://doi.org/10.1007/s11657-018-0510-0
doi: 10.1007/s11657-018-0510-0
Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV; Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25. https://doi.org/10.1007/s11657-016-0278-z
doi: 10.1007/s11657-016-0278-z
Ejlsmark-Svensson H, Rolighed L, Harsløf T, Rejnmark L (2021) Risk of fractures in primary hyperparathyroidism: a systematic review and meta-analysis. Osteoporos Int 32:1053–1060
doi: 10.1007/s00198-021-05822-9
Axelsson KF, Wallander M, Johansson H, Harvey N, Vandenput L, McCloskey E, Liu E, Kanis JA, Litsne H, Lorentzon M (2022) Analysis of comorbidities, clinical outcomes, and parathyroidectomy in adults with primary hyperparathyroidism. J Am Med Assoc Network Open 5(6):e2215396. https://doi.org/10.1001/jamanetworkopen.2022.15396 . (Jun 1)
doi: 10.1001/jamanetworkopen.2022.15396
Yu N, Donnan PT, Flynn RW, Murphy MJ, Smith D, Rudman A, Leese GP (2010) Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 73:30–34
Wermers RA, Griebeler ML, Thapa P, Hathcock MA, Kearns AE (2021) Survival in primary hyperparathyroidism over five decades (1965–2010) a population-based retrospective study. Bone 152:116099. https://doi.org/10.1016/j.bone.2021.116099
doi: 10.1016/j.bone.2021.116099
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–90
doi: 10.2147/CLEP.S91125
Matzen J, Bislev LS, Sikjær T, Rolighed L, Hitz MF, Eiken P, Hermann AP, Jensen JB, Abrahamsen B, Rejnmark L (2022) The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study. BMC Endocr Disord 22(1):14. https://doi.org/10.1186/s12902-021-00918-z . (Jan 6)
doi: 10.1186/s12902-021-00918-z
Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244
doi: 10.1359/jbmr.2002.17.7.1237
Albertsson-Wikland K, Mårtensson A, Sävendahl L, Niklasson A, Bang P, Dahlgren J, Gustafsson J, Kriström B, Norgren S, Pehrsson NG, Odén A (2016) Mortality Is not Increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab 101:2149–2159
doi: 10.1210/jc.2015-3951
Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ: 1–406
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397
doi: 10.1007/s00198-007-0543-5
Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, Wm O, Bl R (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707
doi: 10.1359/jbmr.1999.14.10.1700
Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, Banti C, Del Fiacco R, Bilezikian JP, Pinchera A, Marcocci C (2009) Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 94:2306–2312
doi: 10.1210/jc.2008-2006
Mosekilde L (2008) Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 69:1–19
doi: 10.1111/j.1365-2265.2007.03162.x
De Geronimo S, Romagnoli E, Diacinti D, D’Erasmo E, Minisola S (2006) The risk of fractures in postmenopausal women with primary hyperparathyroidism Eur. J Endocrinol 155:415–420
Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu M, Vandenput L, McCloskey E (2021) The effect on subsequent fracture risk of age, sex and prior fracture site by recency of prior fracture. Osteoporos Int 32:1547–1555
doi: 10.1007/s00198-020-05803-4
Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, Zhang C, McMahon DJ, Romano M, Dworakowski E, Costa AG, Cusano N, Irani D, Cremers S, Shane E, Guo XE, Bilezikian JP (2013) Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res 28:1029–1040
doi: 10.1002/jbmr.1841
Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a non-invasive analytical method based upon the DXA image. J Bone Miner Res 29:518–530
doi: 10.1002/jbmr.2176
Romagnoli E, Cipriani C, Nofroni I, Castro C, Angelozzi M, Scarpiello A, Pepe J, Diacinti D, Piemonte S, Carnevale V, Minisola S (2013) “Trabecular Bone Score” (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 53:154–159
doi: 10.1016/j.bone.2012.11.041
Pretorius M, Lundstam K, Heck A, Fagerland MW, Godang K, Mollerup C, Fougner SL, Pernow Y, Aas T, Hessman O, Rosén T, Nordenström J, Jansson S, Hellström M, Bollerslev J (2020) Mortality and morbidity in mild primary hyperparathyroidism: results from a 10-year prospective randomized controlled trial of parathyroidectomy versus observation. Ann Intern Med 175(6):812–819
doi: 10.7326/M21-4416

Auteurs

John A Kanis (JA)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. w.j.pontefract@shef.ac.uk.
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. w.j.pontefract@shef.ac.uk.

Nicholas C Harvey (NC)

MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Enwu Liu (E)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

Liesbeth Vandenput (L)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Sahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Mattias Lorentzon (M)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Sahlgrenska Osteoporosis Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Region Västra Götaland, Geriatric Medicine, Sahlgrenska University Hospital, Molndal, Sweden.

Eugene V McCloskey (EV)

Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.

Roger Bouillon (R)

Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Louvain, Belgium.

Bo Abrahamsen (B)

Department of Clinical Research, University of Southern, Denmark and Odense University Hospital, Odense C, Denmark.
Department of Medicine, Holbæk Hospital, Holbaek, Denmark.
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Windmill Road, Oxford, OX3 7LD, UK.

Lars Rejnmark (L)

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Helena Johansson (H)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
Sahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH